Core Scientific, Inc./tx (CORZ) · Aug 27, 2026 · New debt

Core Scientific adds $600M bank facility, but only $100M is cash liquidity

$600M credit facility — $100M revolver plus $500M letter-of-credit facility; no funded borrowing disclosed

Core Scientific secures a longer-dated credit backstop, though the actual revolving borrowing capacity is just $100 million.

The filing delivers financing flexibility, not fresh cash. Core Scientific entered a new credit agreement dated August 25, 2026, but the filing does not disclose that any revolving loans were drawn at closing. The facility consists of a $100 million revolver and a $500 million letter-of-credit facility, so the headline $600 million commitment materially overstates immediately usable cash liquidity. 〔0〕

FacilityCommitmentPricing / feeMaturity
Revolving facility$100 millionTerm SOFR + 1.75%; 0.25% unused fee3 years, with a one-year extension option
Letter-of-credit facility$500 millionParticipation fee tied to revolver pricing; 0.125% fronting feeSame maturity framework
Liquidity covenantMinimum $150 millionIncludes cash plus unused revolver capacityTested quarterly

The main improvement is tenor and structure. The agreement gives the company a three-year bank facility, extendable to four years at its discretion, replacing a short-term funding mindset with a more durable liquidity backstop. That is useful for working capital and project-related credit support, but the filing does not provide evidence of lower debt, refinancing savings, or cash proceeds.

Lender protections are meaningful, limiting the upside signal. Borrowing is conditioned on at least $150 million of liquidity and a market capitalization of at least $3 billion; the company can cure a liquidity shortfall with equity issuance, but only a limited number of times. The collateral package covers broad personal property and intellectual property, while project assets can remain outside the collateral pool where project documents restrict pledges. 〔1〕

Net read: a modestly better financing setup, but not a clear earnings-style beat. The market likely expected Core Scientific to maintain financing access as its data-center buildout expands; the new details are the longer maturity, the $500 million LC capacity, and the relatively small $100 million cash revolver. With no funded borrowing, no stated refinancing benefit, and tighter eligibility conditions, this lands as mixed rather than unequivocally positive.

What to watch next

First post-closing quarterly liquidity test after September 30

Original filing on SEC EDGAR

More Core Scientific, Inc./tx news

Core Scientific adds $600M bank facility, but only $100M is cash liquidity | CORZ Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.